ABBV-CLS-628
Phase 2Small molecule
AbbVieABBV-CLS-628 is one of 15 small molecule programs targeting Autosomal Dominant Polycystic Kidney Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Autosomal Dominant Polycystic Kidney Disease
#DrugCompanyPhaseTrials
1Samsca
OtsukaApproved
Afinitor
NovartisApproved
Jardiance
Boehringer IngelheimApproved
Versed
CConrado Roberto Hoffmann Filho
Approved
Lesinurad
EEsperion Therapeutics, Inc.
Approved
Lanreotide Acetate
AAlbireo, an Ipsen Company
Approved
Sandostatin
Sun PharmaApproved
VX-407
Vertex PharmaceuticalsPhase 2
DRSP/EE
Vertex PharmaceuticalsPhase 1
ABBV-CLS-628
AbbViePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ABBV-CLS-628. EMBL-EBI & Wellcome Sanger Institute.
- [4]